ArticleClinical pharmacology and therapeutics2019
Generic Drugs in the United States: Policies to Address Pricing and Competition.
Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Trial
- Article
- Patent challenges without entry? Reassessing first generic exclusivity under the patent-linkage system in South Korea.Globalization and health · 2026Article
- Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA.Journal of general internal medicine · 2026Article
- Sunshine Act expansion and the prescription of generic medications by advanced practice providers.Health affairs scholar · 2026Article
- Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer.PharmacoEconomics - open · 2026Article
- Predicting patent challenges for small-molecule drugs: A cross-sectional study.PLoS medicine · 2025Article
- Survey analysis on comparative use human factors processes.Human factors in healthcare · 2025Article
- Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.Journal of general internal medicine · 2024Article
- Direct-to-Consumer Pharmacies: Disruptive Innovation or More Complexity?Journal of general internal medicine · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?The Journal of clinical endocrinology and metabolism · 2024Review
- Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects.BMC medical research methodology · 2024Article
- A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna.European journal of clinical pharmacology · 2024Article
- Generic drugs use during the COVID-19 pandemic among Lebanese patients using psychotropics: An opportunity for generic drug promotion.Journal of generic medicines · 2023Article
- An empirical study of the impact of generic drug competition on drug market prices in China.Frontiers in public health · 2023Article
- Patent and Marketing Exclusivities 101 for Drug Developers.Recent patents on biotechnology · 2023Review
- Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.JAMA health forum · 2022Article
- Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The cost of prescription drugs in the United States continues to be a source of concern for patients, caregivers, and policymakers. Drug prices typically decline rapidly once generic drugs receive US Food and Drug Administration (FDA) approval and enter the market, but the past decade has witnessed rising costs and shortages of generic drugs. We describe the strategies used by brand-name manufacturers to undermine generic competition and the reasons underlying the price increases of off-patent drugs, some of which continue to lack any competition from generic versions, and others that have increased in price despite having generic versions. We discuss the FDA's role in addressing drug prices and promoting competition, including recent agency policies to modify its process of reviewing generic drug applications and to prioritize applications for off-patent drugs with few competitors. We also examine proposed policy solutions and research areas that could help address the price increases of off-patent drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.